BUZZ-美國銀行上調評級，Regeneron Pharma 獲利

路透中文

01/08

BUZZ-<a href="https://laohu8.com/S/BAC">美國銀行</a>上調評級，Regeneron Pharma 獲利

1月7日 - ** 製藥商Regeneron PharmaceuticalsREGN.O股價上漲3.7%，報805.32美元

** 美國銀行全球研究將該公司評級從 "跑輸大市 "上調至 "買入"；將PT從627美元上調至860美元。

** 新的PT較上一交易日收盤價上漲約11

** 鑑於標籤更新，券商對新版眼藥 Eylea SD 的看法更為積極

** 我們認為 Dupixent 和進入 2026 年的後期管線資產將帶來可觀的上漲空間" - BofA

** 2025 年股價上漲 8.4

(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601388788"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601388788\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601388788?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-08 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601388788","market":"hk","top_or_hot":-1,"title":"BUZZ-美國銀行上調評級，Regeneron Pharma 獲利","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/BAC\">美國銀行</a>上調評級，Regeneron Pharma 獲利</title></head><body><p><span>1月7日</span><span> - </span>** 製藥商Regeneron Pharmaceuticals<span>REGN.O</span>股價上漲3.7%，報805.32美元</p><p>** 美國銀行全球研究將該公司評級從 \"跑輸大市 \"上調至 \"買入\"；將PT從627美元上調至860美元。</p><p>** 新的PT較上一交易日收盤價上漲約11</p><p>** 鑑於標籤更新，券商對新版眼藥 Eylea SD 的看法更為積極 </p><p>** 我們認為 Dupixent 和進入 2026 年的後期管線資產將帶來可觀的上漲空間\" - BofA</p><p>** 2025 年股價上漲 8.4</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-美國銀行上調評級，Regeneron Pharma 獲利</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-美國銀行上調評級，Regeneron Pharma 獲利\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-01-08 02:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/BAC\">美國銀行</a>上調評級，Regeneron Pharma 獲利</title></head><body><p><span>1月7日</span><span> - </span>** 製藥商Regeneron Pharmaceuticals<span>REGN.O</span>股價上漲3.7%，報805.32美元</p><p>** 美國銀行全球研究將該公司評級從 \"跑輸大市 \"上調至 \"買入\"；將PT從627美元上調至860美元。</p><p>** 新的PT較上一交易日收盤價上漲約11</p><p>** 鑑於標籤更新，券商對新版眼藥 Eylea SD 的看法更為積極 </p><p>** 我們認為 Dupixent 和進入 2026 年的後期管線資產將帶來可觀的上漲空間\" - BofA</p><p>** 2025 年股價上漲 8.4</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元製藥公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL4T3Y81DF:1","article_id":"2601388788","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601388788","pubTimestamp":1767809673,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"** 新的PT較上一交易日收盤價上漲約11** 鑑於標籤更新，券商對新版眼藥 Eylea SD 的看法更為積極 ** 我們認為 Dupixent 和進入 2026 年的後期管線資產將帶來可觀的上漲空間\" - BofA** 2025 年股價上漲 8.4(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"REGN":"再生元制药公司","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4504":"桥水持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4139":"生物科技","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BAC":"美国银行","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","BK4581":"高盛持仓","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC"},"translate_title":"BUZZ-Bank of America Upgrades, Regeneron Pharma Gains","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9,"BAC":0.9},"content_text":"BUZZ-美國銀行上調評級，Regeneron Pharma 獲利1月7日 - ** 製藥商Regeneron PharmaceuticalsREGN.O股價上漲3.7%，報805.32美元** 美國銀行全球研究將該公司評級從 \"跑輸大市 \"上調至 \"買入\"；將PT從627美元上調至860美元。** 新的PT較上一交易日收盤價上漲約11** 鑑於標籤更新，券商對新版眼藥 Eylea SD 的看法更為積極 ** 我們認為 Dupixent 和進入 2026 年的後期管線資產將帶來可觀的上漲空間\" - BofA** 2025 年股價上漲 8.4(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}